Osimertinib as a neoadjuvant therapy in resectable EGFR-mutant non-small cell lung cancer: a real-world, multicenter retrospective study

被引：0
作者：
Li, Jialong [1 ]
Wang, Youyu [2 ]
Zhao, Zerui [3 ]
Wang, Sihua [4 ]
Yan, Wanpu [5 ]
Chen, Xiaohui [6 ]
Chen, Tianxiang [7 ]
Li, Pengfei [8 ]
Wang, Sheng [9 ]
Fang, Qiang [1 ]
Peng, Lin [1 ]
Han, Yongtao [1 ]
Tang, Jian [10 ]
Leng, Xuefeng [1 ]
机构：
[1] Univ Elect Sci & Technol China UESTC, Sichuan Canc Hosp & Inst, Sichuan Clin Res Ctr Canc, Sichuan Canc Ctr,Affiliated Canc Hos,Dept Thorac S, Renmin South Rd 55, Chengdu 610042, Peoples R China
[2] Univ Elect Sci & Technol China Uestc, Sichuan Prov Peoples Hosp, Dept Thorac Surg, Chengdu, Peoples R China
[3] Sun Yat Sen Univ, Dept Thorac Surg, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol Southern China,Canc Ctr, Guangzhou, Peoples R China
[4] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Thorac Surg, Wuhan, Peoples R China
[5] Peking Univ Canc Hosp & Inst, Dept Thorac Surg 1, Key Lab Carcinogenesis & Translat Res, Minist Educ,Peking Univ Sch Oncol, Beijing, Peoples R China
[6] Fujian Canc Hosp, Clin Oncol Sch Fujian Med, Dept Thorac Oncol Surg, Fuzhou, Peoples R China
[7] Shanghai JiaoTong Univ Sch Med, Shanghai Chest Hosp, Dept Oncol Surg, Shanghai, Peoples R China
[8] China Med Univ, Liaoning Canc Hosp & Inst, Canc Hosp, Dept Thorac Surg, Shenyang, Peoples R China
[9] Huazhong Univ Sci & Technol, Hubei Canc Hosp, Tongji Med Coll, Dept Thorac Surg, Wuhan, Peoples R China
[10] Nanchang Univ, Affiliated Hosp 1, Dept Thorac Surg, Yongwai Zhengjie 17, Nanchang 330006, Peoples R China
来源：
TRANSLATIONAL LUNG CANCER RESEARCH | 2024年 / 13卷 / 12期
关键词：
Neoadjuvant; osimertinib; epidermal growth factor receptor (EGFR); non-small cell lung cancer (NSCLC); SYSTEMIC THERAPY; PHASE-II; CHEMORADIATION; SURGERY;
D O I：
10.21037/tlcr-24-541
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: Osimertinib, a third-generation tyrosine kinase inhibitor (TKI), has been authorized for use in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). This study aimed to evaluate the effectiveness and safety of neoadjuvant osimertinib in individuals with resectable locally advanced NSCLC harboring EGFR mutation.Methods: Ten centers located in mainland China took part in a single-arm, real-world, multicenter retrospective study (registration number: ChiCTR2100049954). Enrollment included individuals with lung adenocarcinoma who had EGFR mutations. Following the administration of osimertinib, the patients underwent a surgical procedure for resection. The main endpoint was the objective response rate (ORR). The subsequent endpoint analyzed was the joint assessment of overall survival (OS) and disease-free survival (DFS).Results: From July 31, 2018 to April 28, 2023, a total of 38 individuals were involved and received neoadjuvant osimertinib treatment. The ORR was 60.5% (23/38). Thirty-eight patients underwent surgery, and 36 (94.7%) underwent successful R0 resection. Out of 38 patients, sixteen (42.1%) experienced adverse events (AEs) due to treatment in the neoadjuvant phase, with none of them reaching grade 3. Skin irritation [14 (36.8%)], stomach upset [5 (13.2%)], mouth sores [1 (2.6%)] and increased liver enzyme levels [1 (2.6%)] were the common AEs of treatment. The follow-up period lasted an average of 24.9 months. The 1-year OS rate is 94.2%, while the 2-year OS rate is 89.2%. The 1-year DFS rate is 87.9%, and the 2-year DFS rate remains at 87.9% Conclusions: In the actual clinical setting, osimertinib displays encouraging possibilities as a neoadjuvant therapy for individuals with operable EGFR-mutated NSCLC, exhibiting adequate efficacy and an acceptable safety record. The phase III clinical trial of NeoADAURA is expected to provide further efficacy and safety results
引用
收藏
页码：3344 / 3351
页数：8
相关论文
共 27 条
  • [11] Freites-Martinez A, Santana N, Arias-Santiago S, Et al., Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies, Actas Dermosifiliogr (Engl Ed), 112, pp. 90-92, (2021)
  • [12] Baik CS, Chamberlain MC, Chow LQ., Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer, J Thorac Oncol, 10, pp. 1268-1278, (2015)
  • [13] Herbst RS, Wu YL, John T, Et al., Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial, J Clin Oncol, 41, pp. 1830-1840, (2023)
  • [14] Lv C, Fang W, Wu N, Et al., Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage IIIIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial, Lung Cancer, 178, pp. 151-156, (2023)
  • [15] Peled N, Roisman LC, Levison E, Et al., Neoadjuvant Osimertinib Followed by Sequential Definitive Radiation Therapy and/or Surgery in Stage III Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer: An Open-Label, Single-Arm, Phase 2 Study, Int J Radiat Oncol Biol Phys, 117, pp. 105-114, (2023)
  • [16] Hu Y, Ren S, Yang L, Et al., Osimertinib as Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: A Case Series, Front Pharmacol, 13, (2022)
  • [17] Liu B, Liu X, Xing H, Et al., A new, potential and safe neoadjuvant therapy strategy in epidermal growth factor receptor mutation-positive resectable non-small-cell lung cancer-targeted therapy: a retrospective study, Front Oncol, 14, (2024)
  • [18] Chaft JE, Shyr Y, Sepesi B, Et al., Preoperative and Postoperative Systemic Therapy for Operable Non-Small-Cell Lung Cancer, J Clin Oncol, 40, pp. 546-555, (2022)
  • [19] Wang C, Yuan X, Xue J., Targeted therapy for rare lung cancers: Status, challenges, and prospects, Mol Ther, 31, pp. 1960-1978, (2023)
  • [20] Tsuboi M, Weder W, Escriu C, Et al., Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA, Future Oncol, 17, pp. 4045-4055, (2021)
123